☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
OASIS-2
Eli Lilly Reports Results of Mirikizumab in P-III OASIS-2 Study to Treat Moderate to Severe Plaque Psoriasis
July 17, 2020
Paratek Reports Results of Nuzyra (omadacycline) in P-III OASIS-2 Study for Skin Infections
August 30, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.